Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
By Stephen Nakrosis
Shares of Alpine Immune Sciences were trading sharply higher in Wednesday's after-hours market, following news Vertex Pharmaceuticals agreed to acquire the company in a $4.9 billion deal.
Alpine Immune shares were trading 37% higher in the late-trading market, at $64.34, just under the $65 a share offer from Vertex. The shares ended the day's regular trading with a 21% gain, closing at $47.04.
Earlier Wednesday, Alpine Immune shares hit their highest level since 2015 at $47.84 per share.
After the bell, shares of Vertex Pharmaceuticals has lost just over 1%, to trade at $393.24. They ended the day's regular session with a loss of 1.7%, to close at $397.58.
The deal was unanimously approved by the boards of both companies, and is expected to close later this quarter.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 10, 2024 17:40 ET (21:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software